A novel agent for myeloma causing toxic keratopathy, belantamab mafodotin: a case report and literature review.
Rengin Aslıhan KurtDeniz GörenSehnaz KaradenizMutlu AratAfsun SahinPublished in: Arquivos brasileiros de oftalmologia (2022)
A 60-year-old-male with refractory relapsed multiple myeloma presented with redness, pain, foreign body sensation, and blurred vision in both eyes that gradually increased after his third belantamab mafotodin infusion. Biomicroscopy revealed bilateral microcyst-like epithelial changes and epithelial crystal-like deposits, whereas in vivo confocal microscopy revealed intraepithelial and subepithelial hyperreflective deposits in corneal epithelium. Belantamab mafodotin therapy was discontinued for seven weeks due to corneal toxicity, which cleared progressively. We aim to demonstrate belantamab mafodotin-related corneal toxicity that may be detected using slit lamp and in vivo confocal biomicroscopy.
Keyphrases
- optical coherence tomography
- multiple myeloma
- cataract surgery
- wound healing
- oxidative stress
- single cell
- chronic pain
- high grade
- acute lymphoblastic leukemia
- pain management
- low dose
- acute myeloid leukemia
- neuropathic pain
- stem cells
- hodgkin lymphoma
- spinal cord injury
- bone marrow
- smoking cessation
- mesenchymal stem cells
- raman spectroscopy
- solid state
- cell therapy